Equibles does not estimate personal net worth.
Get an email with a short summary when Vertex Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get VRTX alertsCharles Wagner is recorded as CFO at Vertex Pharmaceuticals Inc (VRTX). The newest filing on record that lists Charles Wagner as CFO at Vertex Pharmaceuticals Inc (VRTX) is dated April 3, 2025. The proxy statement of Vertex Pharmaceuticals Inc reports total compensation of $8,241,809 for Charles Wagner in fiscal 2025, including a base salary of $974,808. Disclosed compensation is on record for 7 fiscal years. Charles Wagner has spoken on 11 earnings calls across 1 company, most recently for Vertex Pharmaceuticals Inc on August 3, 2026. Vertex Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vertex Pharmaceuticals Inc includes Dr. Reshma Kewalramani (CEO), Reshma Kewalramani (CEO and Board Member), Dr. Jeffrey M. Leiden (Chairman) and 7 others.
“As Reshman noted, Vertex's second quarter results demonstrate our consistent, strong performance and attractive growth profile. Second quarter 2026 total revenue of $3.3 billion increased 12% year-over-year, with growth balanced between the U.S. and international markets.”
“Vertex's Q3 2025 double-digit revenue growth demonstrates our consistent strong performance and attractive growth profile. Third quarter 2025 total revenue increased 11% year-over-year to $3.08 billion.”
“Vertex's Q2 2025 revenue growth accelerated as expected, and our results demonstrate our consistent strong performance and attractive growth profile. Second quarter 2025 total revenue increased 12% year-over-year to $2.96 billion.”
“Vertex' excellent start to the year demonstrates once again our consistent strong performance and attractive growth profile.”
“On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Stuart Arbuckle, Chief Operating Officer; and myself. We recommend that you access the webcast slides as you listen to this call.”
Start not stated–present
Last confirmed April 3, 2025
Proxy statement
Start not stated–present
Last confirmed April 2, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Operating and Financial Officer | $974,808 | $8,241,809 |
| 2024 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Financial Officer | $876,443 | $7,999,440 |
| 2023 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Financial Officer | $825,000 | $7,371,751 |
| 2022 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Financial Officer | $793,269 | $5,811,611 |
| 2021 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Financial Officer | $729,615 | $6,223,932 |
| 2020 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Financial Officer | $726,923 | $6,090,390 |
| 2019 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Financial Officer | $492,692 | $3,487,213 |
